array:3 [
  0 => array:8 [
    "idiomaDefecto" => "en"
    "pii" => "S0001731017300911"
    "gratuito" => false
    "doi" => "10.1016/j.ad.2017.02.005"
    "en" => array:2 [
      "titulo" => "Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study"
      "autores" => array:1 [
        0 => array:1 [
          "autoresLista" => "F. Valenzuela, C. de la Cruz Fernandez, R.L. Galimberti, S. Gürbüz, M. McKean-Matthews, L. Goncalves, R. Romiti"
        ]
      ]
    ]
    "fechaPublicacion" => "01-07-2017"
    "highLight" => false
    "esBusqueda" => true
  ]
  1 => array:8 [
    "idiomaDefecto" => "en"
    "pii" => "S0001731024004290"
    "gratuito" => false
    "doi" => "10.1016/j.ad.2024.05.008"
    "en" => array:2 [
      "titulo" => " Comparing the Use of Topical Therapy Along with Anti-IL-17 and Anti-IL-23 to Treat Moderate-to-Severe Psoriasis in the Routine Clinical Practice"
      "autores" => array:1 [
        0 => array:1 [
          "autoresLista" => "S. Berenguer-Ruiz, M. Romero-Dávila, M. Aparicio-Domínguez, M. Olivares-Guerrero, E. Daudén, M. Llamas-Velasco"
        ]
      ]
    ]
    "fechaPublicacion" => "01-07-2024"
    "highLight" => false
    "esBusqueda" => true
  ]
  2 => array:8 [
    "idiomaDefecto" => "en"
    "pii" => "S0001731014700146"
    "gratuito" => false
    "doi" => "10.1016/S0001-7310(14)70014-6"
    "en" => array:2 [
      "titulo" => "Pathogenic role of IL-17 in psoriasis and psoriatic arthritis"
      "autores" => array:1 [
        0 => array:1 [
          "autoresLista" => "A. Chiricozzi"
        ]
      ]
    ]
    "fechaPublicacion" => "01-10-2014"
    "highLight" => false
    "esBusqueda" => true
  ]
]